Novartis AG Expected to Earn Q1 2025 Earnings of $1.93 Per Share (NYSE:NVS)

Novartis AG (NYSE:NVS - Free Report) - Stock analysts at Zacks Research raised their Q1 2025 earnings estimates for Novartis in a report released on Monday, September 30th. Zacks Research analyst E. Bagri now forecasts that the company will earn $1.93 per share for the quarter, up from their prior estimate of $1.92. The consensus estimate for Novartis' current full-year earnings is $7.50 per share. Zacks Research also issued estimates for Novartis' Q3 2025 earnings at $2.20 EPS and FY2025 earnings at $8.26 EPS.

Several other equities research analysts have also recently issued reports on NVS. Barclays raised shares of Novartis to a "strong sell" rating in a research note on Monday, June 24th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $121.00 price objective (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. Bank of America cut Novartis from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $135.00 to $130.00 in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Novartis in a research note on Friday, July 19th. Finally, Jefferies Financial Group downgraded shares of Novartis from a "buy" rating to a "hold" rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $120.70.

Novartis Price Performance

Shares of NYSE:NVS traded down $0.08 during trading on Wednesday, reaching $114.47. The stock had a trading volume of 824,319 shares, compared to its average volume of 1,374,111. The business has a fifty day moving average price of $115.28 and a 200-day moving average price of $106.36. Novartis has a 1-year low of $92.19 and a 1-year high of $120.92. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.72 and a current ratio of 0.93. The stock has a market cap of $233.98 billion, a PE ratio of 15.45, a PEG ratio of 1.73 and a beta of 0.57.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.10. Novartis had a return on equity of 34.56% and a net margin of 33.76%. The company had revenue of $12.87 billion for the quarter, compared to analysts' expectations of $12.24 billion. During the same period in the previous year, the firm posted $1.83 EPS.

Institutional Investors Weigh In On Novartis

Several large investors have recently added to or reduced their stakes in the business. Private Ocean LLC purchased a new stake in shares of Novartis in the 1st quarter valued at approximately $25,000. Richardson Financial Services Inc. acquired a new stake in shares of Novartis in the 4th quarter worth $26,000. Clearstead Trust LLC boosted its holdings in Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company's stock valued at $26,000 after purchasing an additional 114 shares in the last quarter. New Millennium Group LLC purchased a new stake in shares of Novartis in the second quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Novartis during the 2nd quarter worth $29,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.